Antitumor carbazoles
Natural and synthetic carbazoles, either in a pure substituted or in an annellated substituted form, represent an important and heterogeneous class of anticancer agents, which has grown considerably over the last two decades. Many carbazole derivatives have been tested for cyctotoxic activity, some of them have entered clinical trials, but only very few have been approved for the treatment of cancer so far, since the clinical application of many carbazoles has encountered problems like severe side effects or multidrug resistance. Due to their polycyclic, planar and aromatic structure carbazoles are predestined for intercalation into DNA and therefore DNA remains one of the main targets for cytotoxic carbazoles. For many carbazoles cytotoxicity can be related to DNA-dependent enzyme inhibition such as topoisomerase I/II and telomerase. But also other targets such as cyclin-dependent kinases and estrogen receptors have emerged.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 7(2007), 2 vom: 19. März, Seite 247-67 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Asche, Christian [VerfasserIn] |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 02.04.2007 Date Revised 26.10.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM168868199 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM168868199 | ||
| 003 | DE-627 | ||
| 005 | 20231223120053.0 | ||
| 007 | tu | ||
| 008 | 231223s2007 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0563.xml |
| 035 | |a (DE-627)NLM168868199 | ||
| 035 | |a (NLM)17348830 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Asche, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antitumor carbazoles |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2007 | ||
| 500 | |a Date Revised 26.10.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Natural and synthetic carbazoles, either in a pure substituted or in an annellated substituted form, represent an important and heterogeneous class of anticancer agents, which has grown considerably over the last two decades. Many carbazole derivatives have been tested for cyctotoxic activity, some of them have entered clinical trials, but only very few have been approved for the treatment of cancer so far, since the clinical application of many carbazoles has encountered problems like severe side effects or multidrug resistance. Due to their polycyclic, planar and aromatic structure carbazoles are predestined for intercalation into DNA and therefore DNA remains one of the main targets for cytotoxic carbazoles. For many carbazoles cytotoxicity can be related to DNA-dependent enzyme inhibition such as topoisomerase I/II and telomerase. But also other targets such as cyclin-dependent kinases and estrogen receptors have emerged | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Carbazoles |2 NLM | |
| 650 | 7 | |a DNA, Neoplasm |2 NLM | |
| 650 | 7 | |a Intercalating Agents |2 NLM | |
| 700 | 1 | |a Demeunynck, Martine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 7(2007), 2 vom: 19. März, Seite 247-67 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2007 |g number:2 |g day:19 |g month:03 |g pages:247-67 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2007 |e 2 |b 19 |c 03 |h 247-67 | ||